Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Van Baelen K, Nguyen HL, Richard F, Zels G, Karsten MM, Nader-Marta G, Vermeulen P, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Maetens M, Biganzoli E, Wildiers H, Smeets A, Nevelsteen I, Neven P, Floris G, Desmedt C

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Van Baelen K, Nguyen HL, Richard F, Zels G, Karsten MM, Nader-Marta G, Vermeulen P, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Maetens M, Biganzoli E, Wildiers H, Smeets A, Nevelsteen I, Neven P, Floris G, Desmedt C

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet